Breezula® (Clascoterone) For Hair Loss: Is It Ready Yet?

One of the most common questions we hear from patients is, “Should I wait for Breezula instead of starting finasteride?” The short answer is probably not.

Breezula®—a topical formulation of clascoterone—is an emerging treatment being studied for androgenetic alopecia, also known as male pattern hair loss. Its unique mechanism of action has generated excitement among hair restoration specialists because it offers a different way to combat the effects of dihydrotestosterone (DHT), the hormone primarily responsible for pattern hair loss. However, it’s important to separate excitement from evidence.

What Is Breezula?

Breezula is a topical medication containing clascoterone, an androgen receptor antagonist. Unlike finasteride, which lowers DHT production throughout the body, Breezula works by blocking DHT from binding to androgen receptors within the hair follicle.

Think of it this way:

• Finasteride reduces the amount of DHT produced.
• Breezula blocks DHT from acting on the hair follicle.

Both treatments target the same biological pathway, but they do so in different ways.

Interestingly, clascoterone is already FDA-approved as Winlevi®, a topical cream used to treat acne. Breezula is a higher-concentration scalp formulation specifically developed for treating hair loss.

Is Breezula FDA-Approved?

Not yet. Although Breezula has progressed through advanced clinical testing, it has not been approved by the U.S. Food and Drug Administration (FDA) for androgenetic alopecia. Until FDA approval is granted, it remains an investigational treatment.

How Does Breezula Compare with Finasteride?

This is the question everyone wants answered—but at this point, no one can answer it with confidence. There are currently no published head-to-head clinical trials comparing Breezula directly with finasteride. Laboratory studies suggest that clascoterone effectively blocks androgen receptor activity in hair follicle cells. While these findings are encouraging, laboratory results do not always predict how well a treatment will work in patients.

Finasteride, on the other hand, has been studied for more than 25 years and has consistently demonstrated its ability to slow hair loss and improve hair density in appropriately selected patients. For now, finasteride remains the treatment with the strongest scientific evidence.

Could Breezula Have Fewer Side Effects?

Possibly. Because Breezula acts locally on the scalp instead of reducing hormone levels throughout the body, researchers hope it will minimize systemic side effects. This has made it particularly interesting for patients who are hesitant to take oral medications.

Long-term studies of topical clascoterone for acne have not shown clinically significant systemic antiandrogen effects. However, we still need large clinical studies in patients with hair loss before drawing firm conclusions about its long-term safety and effectiveness.

Should You Wait for Breezula?

In most cases, no. Hair loss is progressive. Waiting months—or even years—for an investigational treatment could allow additional hair follicles to miniaturize permanently. 

If you are a candidate for proven treatments such as finasteride, minoxidil, platelet-rich plasma (PRP), or hair transplantation, beginning treatment now generally provides the best opportunity to preserve your existing hair. If Breezula eventually receives FDA approval and demonstrates strong clinical results, it can always be incorporated into your treatment plan later.

Dr. Mohebi’s Perspective

“As a hair restoration surgeon, I am excited whenever a new therapy enters advanced clinical trials. Innovation continues to improve our ability to treat hair loss, and Breezula is one of the more interesting medications currently under development because it targets androgen receptors directly within the hair follicle. 

That said, I believe patients deserve recommendations based on high-quality clinical evidence—not anticipation or marketing. While Breezula is promising, we still need published Phase 3 clinical data before we can accurately determine how effective it is compared with established treatments.

For now, finasteride remains the evidence-based standard for medical treatment of male pattern hair loss, and I continue to recommend proven therapies while following the latest research closely.”

— Dr. Parsa Mohebi

Where Breezula Stands Today

Breezula represents an exciting step forward in hair restoration research. Its topical mechanism offers the possibility of treating androgenetic alopecia while minimizing systemic exposure to medication.

However, until published Phase 3 clinical trial results become available and FDA approval is obtained, finasteride remains the most thoroughly studied and evidence-based medical treatment for male pattern hair loss.

As always, the best hair loss treatment plan is individualized. If you’re considering medical treatment for hair loss, consult with a physician experienced in hair restoration to determine the approach that is most appropriate for your specific situation.

References

1. FDA. Winlevi® (clascoterone cream 1%) Prescribing Information.
2. Gupta AK, Talukder M. Relative efficacy of therapeutic options for androgenetic alopecia. JAMA Dermatology.
3. Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology.
4. Mella JM, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia. Archives of Dermatology.
5. Piraccini BM, Alessandrini A. Androgenetic alopecia: Current and emerging therapies. Dermatologic Therapy.
6. Trüeb RM. Emerging pharmacologic therapies for androgenetic alopecia. Journal of Cosmetic Dermatology.